CJC-1295 No DAC (5mg) / Ipamorelin (5mg)
Combined formulation of two synthetic peptides extensively paired in growth hormone secretagogue research: CJC-1295 No DAC (a GHRH analog) and Ipamorelin (a selective ghrelin receptor agonist). 5mg vial size.
About this formulation
This product combines two synthetic peptides that appear together throughout growth hormone secretagogue research, in a 5mg vial format:
- CJC-1295 No DAC (5mg) — a 29-amino-acid GHRH analog acting at GHRH receptors in the pituitary
- Ipamorelin (5mg) — a selective ghrelin/GHSR-1a receptor agonist with high specificity (minimal observed effects on cortisol, prolactin, or aldosterone in research)
Mechanism in Research Literature
The two peptides act on parallel GH-release pathways:
- CJC No DAC: GHRH receptor activation — "permissive" signaling
- Ipamorelin: ghrelin receptor activation — "stimulatory" signaling
- Combined effect: synergistic GH release greater than either compound alone in research models
- Selectivity profile of Ipamorelin reduces off-target signaling observed with earlier GHRPs
- Short half-lives preserve pulsatile GH release pattern
Research Context
This combination has been investigated in studies exploring:
- Synergistic activation of dual GH-release pathways
- Pulsatile vs. continuous GH elevation pharmacology
- Selectivity of Ipamorelin relative to GHRP-2, GHRP-6, and hexarelin
- Downstream IGF-1 response and tissue effects
Related Research Peptides
This combination appears in literature alongside other GH-pathway compounds including Sermorelin, Tesamorelin, IGF-1 LR3, and the standalone CJC No DAC product. Also available in 10mg/10mg vial format.
For research and educational use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
